Publications
2023
Dutta AK, Alberge JB, Lightbody ED, et al: MinimuMM-seq: Genome Sequencing of Circulating Tumor Cells for Minimally Invasive Molecular Characterization of Multiple Myeloma Pathology. Cancer Discov 13:348-363, 2023
Detappe A, Nguyen HVT, Jiang Y, et al: Molecular bottlebrush prodrugs as mono- and triplex combination therapies for multiple myeloma. Nature Nanotechnology, 2023
Cowan A, Ferrari F, Freeman SS, et al: Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study. The Lancet Haematology 10:e203-e212, 2023
Sklavenitis-Pistofidis R, Aranha MP, Redd RA, et al: Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma. Cancer Cell 40:1358-1373.e8, 2022
Detappe A, Nguyen HVT, Jiang Y, et al: Molecular bottlebrush prodrugs as mono- and triplex combination therapies for multiple myeloma. Nature Nanotechnology, 2023
Cowan A, Ferrari F, Freeman SS, et al: Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study. The Lancet Haematology 10:e203-e212, 2023
Sklavenitis-Pistofidis R, Aranha MP, Redd RA, et al: Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma. Cancer Cell 40:1358-1373.e8, 2022